Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.35 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5192647 | 0.85 | ALDH1A1 (0.48) | CYP3A4ALDH1A1TP53TSHRTDP1 | |
| SCHEMBL5195798 | 0.85 | ALDH1A1 (0.48) | CYP3A4ALDH1A1TP53TSHRTDP1 | |
| SCHEMBL878952 | 0.79 | SMURF2 (0.39) | SMURF2SMURF1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL15806349 | 0.76 | SMURF2 (0.42) | SMURF2SMURF1CYP3A4TP53SLC6A2 | |
| SCHEMBL31089051 | 0.76 | CNR1 (0.39) | CYP3A4ALDH1A1TP53TSHRTDP1 | |
| SCHEMBL3822914 | 0.76 | CA1 (0.43) | CYP3A4ALDH1A1SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL28308049 | 0.76 | SMURF2 (0.38) | SMURF2SMURF1CYP3A4ALDH1A1TSHR | |
| SCHEMBL28854015 | 0.76 | GAA (0.40) | TP53HTR2AHTR2CHTR2B | |
| SCHEMBL24521805 | 0.75 | TDP1 (0.42) | CYP3A4ALDH1A1TP53TSHRTDP1 | |
| SCHEMBL11981506 | 0.74 | SLC6A2 (0.35) | SMURF2SMURF1SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2018-01-04 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. | 2015-04-02 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8946273-B2 | S-Triazolyl alpha-mercapto acetanilides as inhibitors of HIV reverse transcriptase | ARDEA BIOSCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-8552043-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552043-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-7435752-B2 | N[S(4-aryl-triazol-3-yl)α-mercaptoacetyl]-p-amino benozioc acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | ARDEA BIOSCIENCES, INC. | 2008-07-24 | — | — | US | disclosed |
| CN-101083987-A | S-triazolyl alpha-mercaptoacetanilides as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES INC (US) | 2007-12-05 | — | — | CN | disclosed |
| EP-1789039-A2 | S-TRIAZOLYL ALPHA -MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | Ardea Biosciences, Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007050087-A1 | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050087-A1 | N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20060270725-A1 | N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | ARDEA BIOSCIENCES, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006026356-A2 | S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | ARDEA BIOSCIENCES, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094284-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | CD44 4325/4885SMURF2 786/4885SMURF1 1511/4885 |
| US-20060270725-A1 | N[S(4-aryl-triazol-3-yl)alpha-mercaptoacetyl]-p-amino benzoic acids as HIV reverse transcriptase inhibitors | NQO2, NAT1, QPCT | CD44 3865/4885SMURF2 3301/4885SMURF1 3037/4885 |
| US-20180002296-A1 | S-TRIAZOLYL ALPHA-MERCAPTO ACETANILIDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE | SPR, POLR2H, TST | CD44 4325/4885SMURF2 786/4885SMURF1 1511/4885 |
| US-20080176850-A1 | S-Triazolyl Alpha-Mercaptoacetanilides as Inhibitors of Hiv Reverse Transcriptase | SPR, POLR2H, QTRT1 | CD44 4155/4885SMURF2 1037/4885SMURF1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.